The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Poniard Pharmaceuticals Inc.  (PARD) Trade Now »     Rate PARD  -  Discuss PARD  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
66.5%
Top:
100.0%
Rate PARD:



PARD Analysis & Videos »


PARD: Bull or Bear?

Biotech Stocks - Beware of The Covered Call Trap Graphic_rating_buy PARD
Ivo
N/A
 +0.00%
in 8 hours

<> Years ago when I worked in retail brokerage, I knew a broker at another firm, who specialized in pitching covered call plays. He would explain to clients how with covered calls you take your profits upfront and the premium you just collected gives you a nice cushion to the downside. Say you buy stock ABC at $10 and sell the $10.00 strike calls for next month at $2.00. If the stock price at expiration is at or above $10, your calls are assigned at $10 - you break even on the stock, and you keep your $2 premium for each of the calls, for a 20% profit. Even if ABC is down a bit, say at $...
By  Ivan Mutaftchiev   (-1.37%  risk: conservative)  11/25/09 Comment


PARD - Azimuth Opportunity Bets on Poniard's Survival. Should you ? Graphic_rating_buy PARD
Ivo
N/A
 -4.55%
in 23 hours
(closed on 11/25/09)
I was poring over Poniard Pharmaceuticals' past press releases and financial reports this weekend, wondering how close this Biotech really was to shutting its doors forever. Things certainly did not look rosy.

Last Monday, November 16 the company had announced that the pivotal Phase 3 trial of its lead drug Picoplatin on relapsed and progressing cases of Small Cell Lung Cancer (S.C.L.C.) had failed to meet primary endpoint. The news cause the stock to open at $1.77, down form a close of $7.58 on Friday, wiping out 77% of the company's market cap in the blink of an eye. The next day,...
By  Ivan Mutaftchiev   (-1.37%  risk: conservative)  11/25/09 Comment


10 Extreme Trades on Pending Clinical Trial Results Graphic_rating_buy PARD
Mikerun
73%
 -48.75%
in 186 days
(closed on 11/16/09)
10 Extreme Trades on Pending Clinical Trial Results
 
 
<> As a follow-up to my recent <font> article on nine extreme FDA trades </font> of pending new product decisions among small and micro-cap companies, I have examined the <font> BioMedReports.com Clinical Trial Calendar </font> database to find companies with market caps below $250M which have pending Phase 2 or 3 clinical trial results expected before the end of 2009. Below is a sample of 10 stocks meeting this criter...
By  Mike Havrilla   (+1.04%  risk: conservative)  05/14/09 Comment


Get free stock alert for PARD:
Your Email Address:


New Index of Cancer Diagnostic and Therapeutic Stocks Graphic_rating_buy PARD
Mikerun
73%
 +50.94%
in 32 days
(closed on 05/14/09)
By Mike Havrilla on 4/12/09 at BioMedReports.com
 
The table at the link below includes statistics for the 40 companies in the ETF Innovators Emerging Cancer Diagnostic and Therapeutic Stock Index, which is featured at BioMedReports.com in the health indexes section of the site. The index will track the performance of stocks with market caps below $200M at the inception date of 4/12/09 from a starting value of 2,632.
 
 
<> A World Health Organization report released last year es...
By  Mike Havrilla   (+1.04%  risk: conservative)  04/12/09 Comment


Poniard Pharma Restructures to Conserve Cash Graphic_rating_buy PARD
Mikerun
73%
 +15.84%
in 23 days
(closed on 04/12/09)
Visit the BioMedReports.com research section to view or download the PDF for Poniard Pharma (PARD) along with other free PDF stock research reports, corporate investor presentations, and fact sheets: http://biomedreports.com/research.html
 
PARD conserves its cash, focusing all efforts on Picoplatin
<>
PARD: Price: $1.94; Market Cap (MM): $62.1
Market Outperform; Target Price: $10.00

Simos Simeonidis, Ph.D. - Senior Biotech Analyst, Rodman & Renshaw

PARD announces minor restructuring . This morning, Poniard announced that the company wi...
By  Mike Havrilla   (+1.04%  risk: conservative)  03/20/09 Comment


Poniard Pharma Awaits Key Cancer Drug Data Graphic_rating_buy PARD
Mikerun
73%
 +1.67%
in 3 days
(closed on 03/20/09)

Visit the www.BioMedReports.com research section to view or download the six page PDF for Poniard Pharma (PARD) along with other free PDF reports and presentations:

http://biomedreports.com/research.html

PARD: Price: $1.87; Market Cap (MM): $64.9

Market Outperform; Target Price: $10.00

Simos Simeonidis, Ph.D. - Senior Biotech Analyst, Rodman & Renshaw

KPMG's "going concern" a non-issue should picoplatin work in SPEAR

<> <> 4Q08 results in line with expectations. Poniard announced financial results for the Q4 and FY08. For the quarter, ...
By  Mike Havrilla   (+1.04%  risk: conservative)  03/17/09 Comment


Poniard Pharmaceuticals: Platinum Rediscovered (Part II) Graphic_rating_buy PARD
-52.27%
in 519 days

This article will discuss the development of Poniard’s lead drug, picoplatin, for the treatment of small cell lung cancer [SCLC]. A General introduction for picoplatin can be found in the first part of this article.

<o:p> </o:p>
By  Ohad Hammer   (+0.15%  risk: moderate)  06/24/08 Comment


Poniard Pharmaceuticals: Platinum Rediscovered (Part I) Graphic_rating_buy PARD
+11.96%
in 25 days
(closed on 06/24/08)
<><>Forty years after the accidental discovery of their anti-cancer properties, platinum based compounds represent one of the most important classes of oncology drugs. Platinum compounds are effective in treating a wide array of malignancies including lung, ovarian and colorectal cancers. Cisplatin was the first approved platinum drug (1978) followed by carboplatin (1989) and oxaliplatin (2002), which together generated annual worldwide sales of approximately $3 billion in 2007. These drugs exert their antitumor activity by binding to DNA and interfering with DNA replication, ultimately leading...
By  Ohad Hammer   (+0.15%  risk: moderate)  05/30/08 Comment


Get free stock alert for PARD:
Your Email Address:





People Bullish on PARD

Ivo
Ivan Mutaftchiev
Analyst
N/A
about 8 hours ago

anatapa
Analyst
N/A
about 1 mo ago

Ohad Hammer
Tracked Blogger
N/A
about 1 year ago

rustus
Analyst
58%
about 1 year ago

parkdawg
Analyst
12%
over 2 years ago


People Bearish on PARD

zerofootprint3@hotmail.com
Analyst
N/A
6 days ago

ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.25% 380
2 Gerald Greene 18.14 +72.34% 210
3 stockmarketfunding.com 17.66 +25.65% 55
4 akiralegrand 13.47 +14.32% 61
5 anup2104 12.13 +76.91% 39


POPULAR STOCKS
Symbol Company Name Sentiment
F Ford Motor Company
POT Potash Corp. of Saskatchewan Inc.
PG The Procter & Gamble Company
SIRI Sirius Satellite Radio Inc
MSFT Microsoft Corp
AMD Advanced Micro Devices Inc

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on PARD


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About Poniard Pharmaceuticals Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch